Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

NCT03653247 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT03653247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03653247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease
Lead sponsor
Sangamo Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
March 6, 2019
Completion date
July 17, 2025
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease